The FDA has approved three new targeted therapies for different stages of advanced prostate cancer: Truqap for PTEN-deficient tumors, rucaparib for BRCA-mutated castration-resistant disease, and Akeega for BRCA2-mutated castration-sensitive cancer.
PARP inhibitors remain strongest in BRCA1/2-altered tumors as use beyond that group has been uneven. In June 2025, the FDA narrowed Zejula’s first-line ovarian maintenance indication to HRD-positive tumors only.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06915025 |
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer |
RECRUITING | PHASE3 |
| NCT06433219 |
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06412120 |
Study Evaluating Safety, Tolerability, and Metabolism of Niraparib |
RECRUITING | PHASE4 |
| NCT06388733 |
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05784012 |
Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT05694715 |
Combination Therapy in Cancers With Mutations in DNA Repair Genes |
RECRUITING | PHASE1 |
| NCT05523440 |
Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation |
TERMINATED | PHASE2 |
| NCT05406700 |
Niraparib In Recurrent IDH 1/2 Gliomas |
ACTIVE_NOT_RECRUITING | EARLY_PHASE1 |
| NCT04992013 |
Niraparib in Tumors Metastatic to the CNS |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT04947254 |
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer |
RECRUITING | PHASE2 |
